EXEL (exelixis.com) מקדם שווי פעילות להכנסות

סמלים רשמיים של חברת Exelixis Inc (EXEL)

Exelixis, Inc. (EXEL) funds the search for new molecules using profits from its flagship drug. On GURU.Markets, the company's price-to-sales multiple shows a peak, where the 6141.08 mark indicates the level of investor confidence. While risks are tied to patent expirations, expanding the application of therapy for advanced renal cell carcinoma helps the brand maintain its leadership in the precision oncology sector.

exelixis.com (EXEL): מכפיל EV/Sales מ-23.11.2025 עד 20.11.2026

פילוחי מדדים פיננסיים ומדדי שוק עבור Exelixis (EXEL)

- מחיר ותחזית קונצנזוס למחירים:
- מדדי הערכת שווי שוק של העסק:
הערכת שווי פונדמנטלית של החברה:Exelixis, Inc. EXEL
דוגמת מוצר של exelixis.com

Steady demand for Cabometyx provides Exelixis, Inc. (EXEL) with high operational efficiency and a sustainable cash flow. The company's EV/Sales ratio compares the total enterprise value, including debt, with sales volume, allowing for a valuation of the market price of one dollar of revenue without distortions from the capital structure. This chart confirms the asset's fundamental reliability, supporting a premium valuation driven by the exceptional margins of targeted therapy.